Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
NASDAQ:AMEX Investor Relations:
ir.canfite.com
Company Research
Source: GlobeNewswire
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Israeli Patent Office has allowed its patent application No. 284463, titled “An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect.” The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including the Company’s lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders. This allowance represents a key addition to Can-Fite’s expanding global intellectual property portfolio around Namodenoson’s anti-obesity activity and follows similar patent advancements in other major jurisdictions including the US, Canada
Show less
Read more
Impact Snapshot
Event Time:
CANF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CANF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CANF alerts
High impacting Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CANF
News
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsGlobeNewswire
- Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study [Yahoo! Finance]Yahoo! Finance
- Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer StudyGlobeNewswire
- Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of NamodenosonGlobeNewswire
- Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity TherapyGlobeNewswire
CANF
Sec Filings
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- CANF's page on the SEC website